SLXN
Silexion Therapeutics Ltd.
通常取引データ（自動更新なし）RVOL 0.2xDV $32,73420日平均DV $215,351?
Earnings 2026-11-1152W high -94.7%52W low +81.9%Market cap $787,712Avg volume 531K
Company Overview
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | 5.17 | $0 | -$3M |
| 2026 Q1 | -8.50 | $0 | -$4M |
| 2025 Q4 | -14.10 | $0 | -$3M |
| 2025 Q3 | -28.80 | $0 | -$3M |
| 2025 Q2 | -43.19 | $0 | -$3M |
| 2025 Q1 | -2.60 | $0 | -$2M |
| 2024 Q4 |
